原发纵隔大B细胞淋巴瘤的研究进展  

Progress of primary mediastinal large B-cell lymphoma

作　　者：余雅亭 王化泉[1] Yu Yating;Wang Huaquan(Department of Hematology,General Hospital,Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院血液科,天津300052

出　　处：《白血病．淋巴瘤》2021年第10期637-640,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(81170472);天津市科技重大专项与工程(18ZXDBSY00140)。

摘　　要：原发纵隔大B细胞淋巴瘤(PMBCL)是一种原发于纵隔的侵袭性大B细胞淋巴瘤,由于其独特的临床和组织学特征,世界卫生组织淋巴肿瘤分类将PMBCL重新分类为一个单独的实体。PMBCL的诊断主要依赖于病理学特征、影像学检查和临床特征等。当前针对PMBCL的治疗方案有很多种,最常用的是R-CHOP和R-EPOCH方案等。放疗对部分患者有益,但也可以导致远期毒性。新药的研发也在不断进行,包括嵌合抗原受体T细胞疗法、抗程序性死亡受体1药物等,治疗后疗效判断和指导下一步的治疗策略主要依赖PET-CT。Primary mediastinal large B-cell lymphoma(PMBCL)is an aggressive large B-cell lymphoma originating in the mediastinum.Because of its distinct clinical and histological features,PMBCL has been reclassified as a separate entity by the World Health Organization classification of lymphoid neoplasms.The diagnosis of PMBCL mainly depends on the pathological features,imaging examination and clinical features.Currently,there are many therapeutic schemes for PMBCL,the most commonly used schemes are R-CHOP and R-EPOCH regimens.Radiotherapy is beneficial in some patients,but it can also lead to long-term toxicity.Research and development of new drugs are ongoing,including chimeric antigen receptor T-cell therapy,anti-programmed death receptor 1 drugs,etc.PET-CT is mainly used to assess the curative effect after treatment and to guide the next treatment strategy.

关 键 词：纵隔肿瘤 淋巴瘤 B细胞 诊断 免疫疗法 抗肿瘤联合化疗方案 放射疗法 

分 类 号：R734.5[医药卫生—肿瘤]